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Abstract: Tyrosine kinase inhibitors (TKI) such as the BCR-ABL inhibitor dasatinib and nilotinib
are highly effective therapies for chronic myeloid leukemia (CML). However, several lines of
evidence suggest that dasatinib can induce bleeding which may be due to impaired collagen-induced
platelet adhesion, aggregation, and secretion. Sarcoma family kinases (SFK) play central role in
the GPVI-induced signaling pathway. We aimed to investigate whether and how dasatinib can
modulate SFK-mediated platelet procoagulant activity in a purified system and in dasatinib/nilotinib
treated CML patients. In platelet rich plasmas of healthy volunteers, dasatinib dose-dependently
reduced convulxin-induced phosphatidylserine exposure and attenuated thrombin formation.
Similarly to these changes, integrin activation and clot retraction were also significantly inhibited
by 100 nM dasatinib. Platelets isolated from dasatinib treated patients showed a significantly lower
phosphatidylserine expression upon convulxin activation compared to premedication levels. In these
samples, thrombin generation was significantly slower, and the quantity of formed thrombin was less
compared to the trough sample. Western blot analyses showed decreased phosphorylation levels of
the C-terminal tail and the activation loop of SFKs upon dasatinib administration. Taken together,
these results suggest that dasatinib inhibits the formation of procoagulant platelets via the GPVI
receptor by inhibiting phosphorylation of SFKs.
Keywords: bleeding; dasatinib therapy; glycoprotein VI; platelet activation; thrombin formation
1. Introduction
Tyrosine kinase inhibitors (TKIs) are widely used drugs as a targeted strategy for cancer treatment
with the aim of prolonging progression-free survival. Deregulated tyrosine kinase activity of the
BCR-ABL oncoprotein is the biochemical hallmark of Philadelphia chromosome-positive (Ph+)
hematological malignancies. Currently, several generations of BCR-ABL TKIs are in clinical use
for treatment of these malignancies. Introduction of the second-generation TKIs, nilotinib and dasatinib
as first-line treatment resulted in rapid and deep reduction of BCR/ABL1 allele transcripts, and this
provided a possibility for long-term survival in CML [1,2]. In addition to CML, several other patient
populations were identified that undoubtedly benefited from TKI treatment. Patients with Ph+ adult
acute lymphoblastic leukemia (ALL) may also benefit from an alternate TKI therapy [3]. In the
treatment of pediatric patients with Ph+ ALL the addition of TKIs to conventional chemotherapy has
improved outcomes of patients [4]. It has long been known that second-generation TKIs may have side
effects as nilotinib can potentiate a prothrombotic state [5] while dasatinib is known to cause platelet
dysfunction e.g. impaired collagen-induced platelet adhesion and aggregation [6,7]. Although both
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drugs bind to the ATP binding site of the kinase domain of the BCR/ABL protein they have different off
target inhibitory effect on several other tyrosine kinases. Dasatinib is a potent multikinase inhibitor,
including c-KIT, EPHA2, platelet-derived growth factor receptor-β, and SFKs. Nilotinib is also a
second generation TKI with a broad inhibitory spectrum of various tyrosine kinases (PDGFR, c-KIT,
ARG, EPHB4), but it does not inhibit SFKs [8]. Previous in vitro and ex vivo studies with dasatinib
have demonstrated a faulty platelet aggregation. On the contrary nilotinib has no effect on platelet
aggregation, at all. Therefore, we used nilotinib as a negative control in our experiments.
Sarcoma family kinases (SFKs) are critical regulators of platelet signaling and activation. These
kinases play a central role in mediating rapid response of platelets to vascular injury. They transmit
activation signals from several various platelet receptors. There are numerous members of this group
and among the SFKs Lyn, Fyn, and Src have been implicated in activation of the GPVI receptor and
the integrin receptor signaling and are frequently studied proteins as they are present in both human
and mouse platelets [9]. TKIs have a different off-target multikinase inhibitory effect. Comprehensive
drug-protein interaction profiles were described [10] to predict the potential side effects of BCR-ABL
TKIs. It was found that the most prominent dasatinib-targeted SFKs are Lyn, Fyn, and Src, kinases
and their negative regulator C-terminal Src kinase (Csk), but nilotinib does not bind to these kinases.
During vascular injury it is primarily the subendothelial collagen that activates platelets and result in
subsequent platelet aggregation. A population of the collagen-adhered platelets responds by surface
exposure of the procoagulant phosphatidylserine (PS). This surface expressed PS facilitates the binding
of coagulation factors and by this promotes thrombin generation [11]. In addition, platelets participate
in fibrin formation and regulate the process of clot retraction [12].
We intended to investigate whether dasatinib also affects the platelet procoagulant activity and
thereby coagulation. For this reason, we examined the in vitro and ex vivo effects of dasatinib on
platelet procoagulant response in dasatinib treated platelets of healthy volunteers and in samples
derived from CML patients on dasatinib therapy. We found that at therapeutic concentration dasatainib,
but not nilotinib, has a strong inhibitory effect on platelet procoagulant activity and on clot retraction
both in non activated as well as in convulxin activated platelets.
2. Results
2.1. Dasatinib Suppresses Convulxin-Induced PS Exposure and Attenuates Thrombin Generation in Vitro
Platelets play a central role in the primary hemostasis and are also actively involved in cell-based
thrombin generation. PS on platelets potentiates thrombin generation by harboring the coagulation
factors. We first investigated the effect of dasatinib and nilotinib on the PS expression of resting and
convulxin activated platelets. Pretreatment of platelets with 100 nM dasatinib caused significant
reduction of PS expression even in non-activated samples. The GPVI agonist convulxin caused a
definitely higher PS expression compared to non-activated platelets, which was abolished by 100 nM
dasatinib pretreatment. Low concentration of dasatinib (10 nM) and nilotinib did not affect PS
expression neither in non activated nor in convulxin activated samples (Figure 1A). In the same
experiments, the modulatory effect of dasatinib on the thrombin generation was investigated. The
thrombin generation test (TGT) can be executed both in platelet poor plasma (PPP) and in platelet rich
plasma (PRP). In case of PPP thrombin generation is elicited by the simultaneous addition of tissue
factor (TF) and phospholipids (PL) while in case of PRP the activator is only TF and the PL is provided
by the activated platelet surface lipids. TGT is a more sophisticated test than the conventional PT and
APTT as it monitors the whole process of thrombin formation while for the fibrin formation in the
conventional clotting time assays roughly 5% of the total thrombin is sufficient. The Thrombinoscope
software was used to monitor the rise and fall of thrombin formation in clotting PRP and these changes
were illustrated by the thrombin generation curve (Thrombogram). Thrombograms were characterized
by the following parameters calculated and presented by the Thrombinoscope software: (i) Lagtime,
the moment at which thrombin generation starts (minutes); (ii) Time to Peak, the time until the Peak
Int. J. Mol. Sci. 2019, 20, 5430 3 of 14
Thrombin (minutes); (iii) Peak Thrombin, the highest thrombin concentration (nM); (iv) Endogenous
Thrombin Potential (ETP), the area under the curve (nM × min).
Representative thrombin generation curves demonstrate the effect of convulxin and dasatinib
or nilotinib on thrombin formation by platelets (Figure 1B). Thrombin formation was faster, and the
lagtime and time to peak values were significantly shorter in convulxin activated samples compared
to the non activated samples (Figure 1C,D). Activation by convulxin increased the peak thrombin
but did not affect the ETP values. High concentration of dasatinib (100 nM) significantly delayed
thrombin generation in the convulxin activated samples but did not affect the non activated samples
(Figure 1C,D). In addition, 100 nM dasatinib also significantly attenuated the peak thrombin but had
no effect on the ETP (Figure 1E,F) in the convulxin activated sample.
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Figure 1. Dasatinib inhibits convulxin-induced procoagulant phosphatidylserine (PS) exposure and
thrombin generation in vitro. Platelet rich plasma (PRP) from healthy donors were incubated with
10 or 100 nM dasatinib, 5000 nM nilotinib or vehicle (0.2% DMSO) for 10 min. Platelets, pretreated
with vehicle (without Tyrosine kinase inhibitors (TKI)) or TKI, subsequently they were stimulated with
12.5 ng/mL convulxin for 15 min. Exposure of PS was determined by FITC-labeled annexin V (A). The
histogram shows percentages of platelets binding FITC-annexin V. Representative thrombin generation
curves of TKI pretreated and convulxin stimulated PRPs (B). Lagtime (C), time to peak (D), peak
thrombin (E), and Endogenous Thrombin Potential (ETP) (F) parameters were evaluated. The results
are the mean ± SEM of five different experiments.
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2.2. Dasatinib Inhibits the Activation of Integrin αIIbβ3 and Clot Retraction
Flow cytometry was used to determine the effect of dasatinib on integrin αIIbβ3 activation by
PAC1 binding. Dasatinib at 100 nM significantly reduced the level of activated integrin in non activated
sample and strongly inhibited the integrin activation that was elicited by the GPVI receptor agonist,
convulxin (Figure 2A). Clot retraction was assayed for 60 min. At the end of the incubation period, the
non activated sample displayed intense clot retraction. In samples, where platelets were activated by
convulxin, the clot contraction was less intense. However, 100 nM dasatinib pretreatment significantly
increased the volume of the extruded serum in the convulxin activated sample (Figure 2B,C). Nilotinib
pretreatment had no effect on integrin activation or clot retraction.
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Figure 2. Inhibitory effect of dasatinib on convulxin-induced integrin αIIbβ3 activation and clot
retraction. Platelets in control PRPs were pretreated with asatinib/nilotinib or vehicle (without TKI)
and subsequently were stimulated with convulxin. The active conformatio of the integrin αIIbβ3 was
detected by FITC-labeled PAC1 monoclonal a tibody and analyz d by flow cytometry. The percentages
of platelets binding FITC-PAC1 are shown (A). Clot retraction of platelets was elicited by high calcium
con tration in TKI pretreated and convulxin-activated PRPs (B). Results were expr ssed as extru ed
percent of the original volume. The results are the mean ± SEM of 5 different experiments. Panel (C)
shows a photo se ies to res the clot etraction phenom non.
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2.3. Dasatinib but Not Nilotinib Treatment of CML Patients Considerably Alters PS Exposure and
Thrombin Generation
Peripheral blood samples of TKI treated CML patients were drawn immediately before and at 1 h
after witnessed dasatinib/nilotinib administration. PRPs were separated by centrifugation, and a part
of the samples were activated by convulxin. Similarly to the in vitro experiments, the procoagulant
activity of platelets was examined by detecting PS expression and measuring thrombin generation. The
PS expression was completely suppressed on the platelet surface at 1 h after dasatinib treatment both
in non activated and convulxin activated samples (Figure 3A). Nilotinib treatment had no inhibitory
effect on PS expression neither in non activated nor in convulxin activated samples (Figure 4A). Effect
of dasatinib/nilotinib treatment on thrombin generation was shown by representative thrombograms
(Figures 3B and 4B). The kinetics of thrombin generation, (lagtime and time to peak) as well as the
quantity of generated thrombin (thrombin peak and ETP) were studied. The time parameters of
thrombin formation were shorter, and the amount of generated thrombin was greater upon convulxin
activation in samples before dasatinib treatment. At 1 h after dasatinib administration the time for
thrombin generation was prolonged (Figure 3C,D) and the quantity of the formed thrombin—peak and
ETP values—were significantly reduced (Figure 3E,F) compared to the premedication samples in both
non activated and convulxin activated samples. In premedication samples of the nilotinib treated group,
convulxin caused similar changes in thrombin generation than in premedication sample of dasatinib
treated group, the time parameters were shortened, and the quantity of generated thrombin was
increased. Unlike in case of dasatinib, in the nilotinib treated group, we could not observe any difference
in thrombin generation between the premedication and postmedication samples (Figure 4C–F).
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Figure 3. Treatment of chronic myeloid leukemia (CML) patients with dasatinib suppresses PS exposure
and generation of thrombin in PRP. Blood was collected from dasatinib treated CML patients (n = 5)
before and at 1 h after witnessed drug administration. Platelets of patients were stimulated with
12.5 ng/mL convulxin for 15 min in PRP. PS exposure (A) and thrombin generation were investigated.
Panel (B) shows representative overlay thrombin generation curves. Time parameters of thrombin
generation, lagtime (C); time to peak (D); and quantity of generated thrombin, peak (E) and ETP (F),
were evaluated.
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Figure 4. Nilotinib treatment does not affect PS expression and thrombin generation in PRP of CML
patients. Samples were from nilotinib treated CML patients (n = 5) before and at 1 h after witnessed
drug administration. Platelets of patients were stimulated with convulxin for 15 min in PRP. PS
exposure (A) and thrombin generation were investigated. Panel (B) shows representative overlay
thrombin generation curves. Time parameters of thrombin generation, lagtime (C); time to peak (D);
and quantity of generated thrombin, peak (E) and ETP (F), were evaluated.
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2.4. Integrin Activation and Clot Retraction were Considerably Affected in PRPs of Dasatinib Treated
CML Patients
Low level of activated integrin αIIbβ3 was observed on the platelets of dasatinib treated group
in the premedication samples, and it was further decreased at 1 h after dasatinib medication. The
amount of activated integrin was increased in the premedication sample of both dasatinib and nilotinib
treated groups upon convulxin stimulation. However, dasatinib treatment considerably inhibited
convulxin-induced integrin activation, whereas nilotinib did not (Figure 5A,B). It could be observed
that clot retraction was intense and definitely similar in premedication and postmedication samples of
dasatinib/nilotinib treated patients (Figure 5C,D). At the same time, the clot retraction became less
intense by convulxin stimulation in premedication samples of the dasatinib or nilotinib treated groups.
It could be observed that dasatinib treatment non significantly attenuated the effect of convulxin that is
exemplified by a considerably increased volume of the extruded serum (Figure 5C).Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 7 of 14 
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Figure 5. Integrin αIIbβ3 activation and clot retraction in PRPs of TKI treated CML patients. Blood was
collected from dasatinib (n = 5) or nilotinib (n = 5) treated CML patients before and at 1 h after witnessed
drug administration. Platelets of patients were stimulated with convulxin in PRP. The percent of active
conformation of integrin αIIbβ3 is shown by FITC-PAC1 binding in the cases of dasatinib or nilotinib
treated patients respectively (Panels A and B). Panels C and D show results of clot retraction in PRPs of
dasatinib or nilotinib treated patients.
2.5. Dasatinib Inhibits Phosphorylation of Regulatory Sites of SFKs
The decreased platelet response to the GPVI agonist convulxin suggested that dasatinib may
influenc platelet signaling via the inhibition of SFKs. Fir t, the platelet lysates of dasatinib/nilotinib
treated CML patients were examined using western blot. W observed that at 1 h fter dasatinib
treatment, the inhibitory phosphorylations of Fyn, Lyn, and Src kinas s were remarkably reduced
(Figure 6A–C) w ile the activation loop phosphorylations were only lightly suppressed o not at
all (Figure 6D,F) compared to the premedication samples. Nilotinib treatment did not cause marked
change in the phos horylation lev l of the regulatory ites. In order to understa d how dasatinib
can aff ct platelet activation, we examined tyrosine phosphorylation f both regulat ry sites of SFKs
in a series of in vitro experiments. Control platelets were treated by dasatinib at 0, 10, and 100 nM
final concentration, and these TKI pretreated platelets were activated by convulxin. In case platelets
were not pretre ted with dasatinib (0 nM) but were activated by convulxin for 15 min, a decreas d
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phosphorylation level was observed in both the C-terminal tail and the activation loop of SFKs. In
line with the previous data, convulxin could result in an attenuated effect in the presence of 10 nM
dasatinib but 100 nM dasatinib abolished this effect (Figure 7).Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 8 of 14 
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Figure 6. Dasatinib inhibits the phosphorylation of C-terminal tail and activation loop of Sarcoma
family kinases (SFK) in CML patients. Lysates of platelets from dasatinib (n = 3) or nilotinib (n = 3)
treated patients were examined with the indicated antibodies against the inhibitory (A–C) and the full
activatory (D–F) phosphorylation of Lyn, Fyn, and Src kinases. The quantity of phosphorylated SFKs
in platelet lysates before drug administration (0) was regarded as 100 %. Columns show the mean
and SEM.
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Figure 7. Phosphorylation status of SFK after dasatinib treatment upon convulxin activation. Gel
filtrated human platelets from a healthy donor were incubated with 10 or 100 nM dasatinib or vehicle
(0.2% DMSO) for 10 min. After incubation, platelets were left non activated or were activated with
12.5 ng/mL convulxin for 15 min. Platelet lysates were immunoblotted with phosphospecific antibodies
against the inhibitory (A) and the full activatory (B) phosphorylation of Lyn, Fyn, and Src kinases.
3. Discussion
The two investigated drugs in this study, although both belong to the second-generation of the
TKIs, exert their off-target effect differently. Dasatinib is a Type I while Nilotinib is a Type II inhibitor.
Type I inhibitors bind at the ATP-binding pocket, which is highly conserved across the human kinome,
and to achieve greater selectivity than ATP, Type I inhibitors typically not only occupy the space where
the ATP adenine group binds but also extends into different proximal regions. Type II inhibitors
bind not only to the ATP adenine group area but also into the allosteric pocket with the benzamide
substituent. Since the ATP-binding site on diverse kinases in the human body is structurally conserved,
it is expected that these compounds may have unintended inhibitory actions at nontarget kinases.
Indeed, several lines of evidence suggest that multi-target TKIs can have a wide range of side effects.
Nilotinib activates the endothelium and platelets in vitro and in vivo and moreover potentiates platelet
adhesion and thrombus formation [5], thus may elicit prothrombotic or atherogenic effects [13,14].
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Contrary to nilotinib, dasatinib was shown to elicit hemorrhagic adverse events in CML patients [15,16].
In vitro and ex vivo studies demonstrated its effect on primary hemostasis. Dasatinib reversibly
inhibits collagen-induced platelet adhesion, activation, and aggregation, and these are mediated by
inhibition of the Src kinase [6]. Similarly to these findings, in our previous study we could observe an
inhibitory effect of dasatinib on collagen-induced platelet aggregation and ATP secretion in in vitro
experiments and ex vivo samples as well [17].
Platelets, upon activation by various agonists, are known to form populations with different
surface properties. These populations of activated platelets also have different functions depending
on their activation state and surface properties. One population of stimulated platelets shows high
level of activated integrin αIIbβ3 to which fibrinogen can bind and this results in platelet–platelet and
platelet–leukocyte aggregation and clot-retraction. Another population exposes surface PS, and these
cells are described as procoagulant platelets. The formation of PS-exposing platelets is linked to a
prolonged, high cytosolic Ca2+ level that is required for swelling and phospholipid scrambling. In
addition, these platelets are characterized by a calpain-mediated inactivation of the αIIbβ3 integrin
and thus can not participate in clot retraction. Thus, there are major differences between aggregatory
and procoagulant platelets.
Procoagulant platelets contribute to fibrin formation, which is initially linked to PS exposure and
secondarily depend on integrin αIIbβ3 activation and transglutaminase-dependent fibrin cross-linking.
Fibrin is preferentially localized near the sites of tissue factor and on procoagulant platelets. The
procoagulant platelets are deposited on the thrombus surface during the contraction process that can
be crucial for the spatial control of thrombin generation and fibrin formation [18]. Coated-platelets are
a subpopulation of thrombocytes formed after stimulation with collagen plus thrombin also express PS
and possess procoagulant properties [11,19]. In platelets, signaling via the GPVI receptor is a major
pathway for the formation of procoagulant platelets [20].
In the present study, we demonstrate for the first time the effects of second-generation TKIs on
the procoagulant activity of platelets. In our in vitro experiments, we used the clinically relevant
concentrations of TKIs [21]. The results of the in vitro experiments clearly showed that at the higher
end of the therapeutic range, dasatinib markedly reduced the convulxin-induced activation response
of isolated platelets, including PS exposure, thrombin formation, integrin activation and subsequent
clot retraction. The inhibitory effect on PS exposure and PAC1 expression was also evident in non
activated platelets. Furthermore, in the ex vivo study carried out in CML patients at 1 h after dasatinib
ingestion, the inhibitory effect of dasatinib on procoagulant properties of platelets was also already
observed in both activated and non-activated samples.
When platelets were activated via the GPVI receptor after dasatinib pretreatment, the effect
of convulxin was completely abolished in the PS dependent tests, and integrin activation and the
clot-retraction were also attenuated. Nilotinib had no effect on the procoagulant activity of platelets
neither in the in vitro nor in the ex vivo experiments. This is in line with results of our previous work
where we found that therapeutic concentration of dasatinib reduced the coated-platelet generation,
and nilotinib had no effect [17]. The inhibitory effect of dasatinib is not limited to the above activation
markers; it also abolishes the alpha granule excretion in platelets that can be monitored by surface
P-selectin expression (Figure S1).
Dasatinib can target SFKs, namely Lyn, Fyn, and Src kinases that are all critical regulators of
platelet signaling and activation. The activity of SFK is regulated through the phosphorylation of
conserved tyrosine residues in the C-terminal tail that inhibits SFK activity and in the activation loop
that maximally active SFK.
Therefore, we studied the phoshorylation status of Lyn, Fyn, and Src at both regulatory sites in
platelets of dasatinib or nilotinib treated CML patients. From our results, we concluded that dasatinib
but not nilotinib inhibits both the maximally active and inactive form of these kinases. This observation
is in accordance with results of the activity-based kinase profiling where dasatinib was found to inhibit
nearly twice as much kinases than nilotinib [22]. The striking difference between the effect of dasatinib
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and nilotinib on platelet procoagulant activity suggests that the major effect of dasatinib may be
mediated by SFK inhibition.
However, from these data, it cannot be concluded that dasatinib directly exerts its inhibitory
effect on platelet procoagulant activity through inhibition of SFKs. Therefore, we examined the
phosphorylation status of SFKs in dasatinib pretreated and convulxin activated platelets. In agreement
with previous reports, we found a decreased phosphorylation level in both the C-terminal tail and
the activation loop of SFKs [23,24] in platelets that were not pretreated with TKI but were activated
by convulxin. In addition, we observed that already at the low end of the therapeutic concentration
dasatinib (10 nM) considerably inhibited both form of SFKs in non activated platelets while at the high
end (100 nM) of the dasatinib therapeutic range SFKs were totally inhibited. In line with previous
changes, when platelets were pretreated with 10 nM dasatinib before activation, convulxin was able to
exert its effect on both forms of SFKs, but 100 nM dasatinib completely abolished this effect. These
effects were the same as we observed for PS expression in the in vitro experiments.
It has long been observed that dasatinib treatment may lead to bleeding symptoms in CML,
which may be due to various reasons. On the one hand, dasatinib treatment may be associated with
mild thrombocytopenia and an increased risk of bleeding [25]. We could not observe any clinical
bleeding symptoms in our dasatinib treated patients and only 1 out of 5 was thrombocytopenic that
further decreased by 29% upon dasatinib intake. On the other hand, dasatinib may cause platelet
dysfunction but no association was found between bleeding symptoms and the impaired platelet
function, and it was concluded that the occurrence of bleeding cannot be predicted by in vitro platelet
aggregation tests [26]. In addition, dasatinib may exert an effect on other elements in the circulation
that can considerably modify the side effects in dasatinib-treated CML patients. Dasatinib triggers a
transient increase in vascular leakage that probably contributes to adverse effects such as bleeding
diathesis. The side effect of dasatinib on the induction of eryptosis in human erythrocytes should not
be neglected. Eryptosis is characterized by cell shrinkage, PS externalization and loss of membrane
integrity. Eryptosis might promote blood coagulation through PS externalization. The effect of
dasatinib on circulation is complex, and the clinical outcome of bleeding might depend on which effect
is ore pronounced, e.g, inhibition or promotion of PS expression on different types of cells [27,28].
In summary, our work demonstrates a novel off-target effect of dasatinib on platelet function and
describes the mechanisms that may lead to the observed phenomena. Our results are in accordance
with conclusions of previous studies since although significant platelet function impairment was also
evident in patients, this did not translate into any clinically significant bleeding. Dasatinib treatment
results in a strong inhibition of GPVI receptor agonist-induced platelet procoagulant activity in vitro
and in CML patients, and this effect may contribute to hemorrhagic consequences of dasatinib treated
patients with endothelial disruption or damage when GPVI activating agonists like subendothelial
collagen is exposed.
4. Materials and Methods
4.1. Materials
Dasatinib and nilotinib for in vitro experiments were from Cayman Chemical (Ann Arbor, MI,
USA). The following directly conjugated monoclonal antibodies were purchased from Becton Dickinson
(San Jose, CA, USA): annexin V-FITC, CD41a-PECy5, CD42a-FITC, CD62P-PE, PAC1-FITC. CD41-PE
was from DAKO (Glostrup, Denmark). Dimethylsulfoxide (DMSO), Sepharose CL-2B, anti-actin and
biotin conjugated anti-rabbit IgG were from Sigma-Aldrich (St. Louis, MO, USA) and convulxin were
from Pentapharm (Basel, Switzerland). For western blot we used the following polyclonal antibodies:
p-Fyn Y530, p-Lyn Y396, p-Src Y529, and p-Src Y418 (Thermo Fischer Scientific, Rockford, IL, USA);
p-Fyn Y416 and p-Lyn Y507 Biorbyt (San Francisco, CA, USA); and Cell Signaling Technology (Leiden,
The Netherlands), respectively. Avidin-biotin complex kit was from Vector Laboratories (Burlingame,
CA, USA), and ECL reagent was used from Millipore (Billerica, MA, USA).
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4.2. Blood Drawing from Healthy Volunteers and Patients
Peripheral blood samples were drawn from five healthy volunteers into tubes containing 0.105 M
sodium citrate.
Healthy volunteers were recruited from the staff of the Department of Laboratory Medicine.
Patients with chronic phase CML on dasatinib (n = 5) or nilotinib (n = 5) therapy were included in the ex
vivo study. All dasatinib treated patients were taking 100 mg QD, and nilotinib treated patients were on
400 mg BID. Patient’s blood was drawn immediately before and 1 h after witnessed drug administration.
Subjects were recruited from the Hematology Outpatient Clinic at the Institute of Internal Medicine
University of Debrecen. Antiplatelet therapy, if any, was suspended 7 days prior to examination. At
the time the samples were taken, all CML patients were on continuous dasatinib/nilotinib treatment
for at least 4 weeks. Informed consent was obtained from all participants (CML patients and healthy
volunteers) in accordance with the local institution review board guidelines. Ethical agreements were
provided by the local ethical committee of the University of Debrecen (identification code: RKEB/IKEB
4875-2017, approval date: September 25, 2017).
4.3. Preparation of Platelet Rich Plasma (PRP) and Design of in Vitro and ex Vivo Study
PRP was prepared from whole blood by centrifugation at 170× g for 15 min at room temperature
(RT). Platelet count of PRP was adjusted to 250 G/L by adding platelet poor plasma (PPP). PPP was
obtained by centrifugation of the citrated blood sample at 1500× g for 15 min at RT.
PRPs from healthy volunteers were used for in vitro experiments of dasatinib/nilotinib effects;
the following PRP samples were prepared: (i) non activated, (ii) dasatinib or nilotinib pretreated non
activated, (iii) convulxin activated, and (iv) dasatinib or nilotinib pretreated and convulxin activated.
For pretreatment dasatinib was used at 10 and 100 nM while nilotinib was used at 5000 nM final
concentration for 10 min at 37 ◦C. Pretreated platelets were activated by GPVI agonist convulxin at
12.5 ng/mL final concentration for 15 min at 37 ◦C without stirring.
In the ex vivo study PRPs of dasatinib or nilotinib, treated CML patients were activated with
convulxin at 12.5 ng/mL final concentration for 15 min at 37 ◦C without stirring thus, (i) non activated
and (ii) convulxin activated samples were created.
4.4. Flow Cytometric Assays
Platelet PS expression was determined by annexin V binding to platelet surface using
FITC-conjugated annexin V and for platelet identification PE-conjugated CD41 monoclonal antibody
was used. Five microliter of PRP was stained with 5 µL of annexin V-FITC and 5 µL of CD41-PE in
35 µL annexin V binding buffer (it provides calcium for binding of annexin V), and the mixture was
incubated for 15 min at RT in the dark. Active conformation of the integrin αIIbβ3 was determined by
binding of FITC-conjugated PAC1 and PECy5-conjugated CD41a antibodies.
Samples were diluted to 550 µL with buffer and measured immediately after staining by an FC500
flow cytometer, and results were analyzed with the Kaluza software (Beckman Coulter, Brea, CA,
USA). P-selectin expression was determined by using PE-conjugated CD62 and CD42a-FITC antibodies.
Convulxin activated or non activated platelets of dasatinib/nilotinib treated CML patients were fixed
by paraformaldehyde and stained by above mentioned monoclonal antibodies.
4.5. Thrombin Generation Assay
Thrombin generation was measured in PRP using Fluoroskan Ascent FL fluorimeter with
Thrombinoscope reagents and software (Thrombinoscope BV, Maastricht, The Netherlands). Assays
were carried out according to the manufacturer’s instructions.
Into wells of a black plate, 80 µL of pretreated PRP and 20 µL of standard preparation containing
1 pM recombinant tissue factor (PRP reagent)/ Thrombin calibrator were pipetted, and after incubation
for 10 min at 37 ◦C, the thrombin generation was started by adding 20 µL of FluCa (fluorogenic substrate
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and calcium in buffer). Fluorescence was detected and the thrombin generation curve was generated.
The kinetics of thrombin generation was characterized by lagtime, time to peak, while the quantity of
generated thrombin was described by thrombin peak end endogenous thrombin potential (ETP).
4.6. Clot Retraction
In the in vitro experiments, 900 µL of PRP was preincubated with 100 µL of buffer control or
different concentrations of dasatinib or nilotinib for 10 min at 37 ◦C in a water bath and subsequently
was activated by convulxin for 15 min at 37 ◦C. In a glass tube, 1000 µL of TKI-pretreated and activated
PRPs from an in vitro experiment, and similarly to this, 1000 µL PRPs from dasatinib/nilotinib treated
CML patients were incubated with 100 µL of 250 mM CaCl2 (at a final concentration of 22.7 mM)
for 60 min at 37 ◦C in a water bath. At the end of incubation, photos were taken to document clot
formation and the volume of the extruded serum was determined.
4.7. Western Blot Analysis
Platelets of dasatinib or nilotinib treated CML patients were purified by gel filtration [17] that was
performed on Sepharose CL-2B column. In the in vitro experiments, control platelets were first gel
filtrated and then were pretreated by dasatinib/nilotinib and subsequently activated by convulxin.
Gel filtrated platelets (4 × 107 from each sample) were lysed with lysis buffer containing 1%
TritonX-100 in PBS supplemented with a cocktail of tyrosine phosphatase inhibitor from Sigma
(St. Louis, MO, USA). Platelet lysates were separated by polyacrylamide gel electrophoresis and
subjected to western blotting. Specific phosphorylation of Lyn, Fyn, and Src kinases were visualized,
using phosphospecific antibodies (Ab) and biotinylated secondary Ab followed by avidin-biotin
complex for 30 min. Bands were demonstrated by enhanced chemiluminescence (ECL).
4.8. Statistical Analysis
GraphPad Prism version 4.0 program was used for the statistical analysis. Data distribution was
evaluated by Kolmogorov–Smirnov test. The statistical significance of the differences between groups
of in vitro experiment was analyzed by one-way ANOVA in case of Gaussian distribution, and by
Kruskal–Wallis test in case of non-Gaussian distribution, as appropriate. The statistical significance of
the differences between before (0 h) and 1 h after drug administration groups of CML patients was
analyzed by paired Student’s t-test in case of Gaussian distribution and by Wilcoxon rank test in case
of non-Gaussian distribution. Differences were considered significant when p values were below 0.05.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/21/
5430/s1.
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